Myocardial InfarctionSTEREO-MINCT07636642
Sixth Generation High-sensitivity Cardiac Troponin T for the Early Rule Out of Myocardial Infarction: a Controlled Before and After Study
A study testing sixth-generation high sensitivity cardiac troponin T assay and fifth-generation high sensitivity cardiac troponin T assay in people with Myocardial Infarction, run by University of Edinburgh at 3 sites in United Kingdom.
Trial summary
Cardiac troponin is a protein released into the blood when the heart muscle is damaged. Measuring this protein helps doctors diagnose a heart attack (also called a myocardial infarction). Modern blood tests, known as high-sensitivity cardiac troponin assays, can detect very small amounts of this protein. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myocardial Infarction
- What is being tested?
- sixth-generation high sensitivity cardiac troponin T assay and fifth-generation high sensitivity cardiac troponin T assay
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 19,500 participants
- Where
- 3 sitesUnited Kingdom
- Study dates
- 1 Jun 2026to May 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years and over.
- Attending clinician suspects acute coronary syndrome.
- At least one measurement of cardiac troponin using the Gen 5 or Gen 6 hs-cTnT assay.
Who cannot join
- Insufficient clinical information to perform record linkage.
- Not resident in Scotland.
- Previous enrolment in the study.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom3 sites, 3 recruiting
- Recruiting
The Royal Infirmary of Edinburgh
Edinburgh, Midlothian, EH16 4SA
Andrew R Chapman, MD PhD, +44131 242 6200, a.r.chapman@ed.ac.uk
Andrew R Chapman, MD PhD
- Recruiting
Western General Hospital
Edinburgh, Midlothian, EH4 2XU
Andrew R Chapman, MD PhD, +44131 242 6200, a.r.chapman@ed.ac.uk
Andrew R Chapman, MD PhD
- Recruiting
St. John's Hospital
Livingston, West Lothian, EH54 6PP
Andrew R Chapman, MD PhD, +44131 242 6200, a.r.chapman@ed.ac.uk
Andrew R Chapman, MD PhD
About this study
Cardiac troponin is a protein released into the blood when the heart muscle is damaged. Measuring this protein helps doctors diagnose a heart attack (also called a myocardial infarction). Modern blood tests, known as high-sensitivity cardiac troponin assays, can detect very small amounts of this protein.
A new version of this test, called Troponin T high-sensitivity Gen 6, has recently been developed and approved for use. It is designed to be more accurate and reliable, detecting smaller changes in troponin levels and being less affected by technical interference. The investigators believe this improved test will allow doctors to diagnose heart attacks more quickly and decide sooner who needs to stay in hospital and who can safely go home. This could help reduce overcrowding in Accident and Emergency (A\&E) departments, a major challenge for the NHS.
Read more
This study will examine whether switching to this new test across a health board shortens the time patients with suspected heart attacks spend in the Emergency Department. The investigators will use information from the DataLoch Heart Disease Registry, which automatically collects anonymised hospital data for patients attending with possible heart attacks. The investigators will compare data from one year before and one year after implementation to see whether average length of stay changes and to confirm that patient safety remains high. This investigators will also measure both the current and new versions of the troponin test in surplus blood samples collected during two six-month periods-one before and one after the new test is introduced. This will allows the investigators to directly compare the two tests reliably.
Patients will not need to do anything extra to take part - the study uses information and samples already collected as part of their usual care.
- Conditions
- Myocardial Infarction
- Being tested
- sixth-generation high sensitivity cardiac troponin T assay, fifth-generation high sensitivity cardiac troponin T assay
- Keywords
- cardiac troponin, myocardial infarction, acute coronary syndrome, accelerated decision pathway, Troponin T high sensitivity generation six
- Medical subject headings
- Myocardial Infarction, Acute Coronary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sixth-generation high sensitivity cardiac troponin T assayDiagnostic test
Also called Troponin T high sensitivity generation six, TnT hs Gen 6
Elecsys Troponin T hs Gen 6 is an immunoassay for the in vitro quantitative determination of cardiac troponin T in human serum and plasma, that can be used as an aid in the differential diagnosis of acute coronary syndrome to identify necrosis, e.g. acute myocardial infarction (AMI). In contrast to the previous generation of the assay (Elecsys Troponin T hs), the Gen 6 assay has been standardised against recombinant human cardiac troponin T, and has been demonstrated to have greater analytical precision and resistance to interference.
fifth-generation high sensitivity cardiac troponin T assayDiagnostic test
Also called Troponin T gen 5
Elecsys Troponin T Gen 5 is an immunoassay for the in vitro quantitative determination of cardiac troponin T in human serum and plasma, that can be used as an aid in the differential diagnosis of acute coronary syndrome to identify necrosis, e.g. acute myocardial infarction (AMI). It is the most widely used high-sensitivity troponin assay globally.
| Study group | Role | What they receive |
|---|---|---|
| Pre-implementation | Active comparator | Consecutive patients presenting with suspected acute coronary syndrome for 12 months prior to the implementation of the sixth generation hs-cTnT assay will be enrolled into the "pre-implementation" arm, where care is guided by the current, fifth-generation assay Receives: Diagnostic Test: fifth-generation high sensitivity cardiac troponin T assay |
| Post-implementation | Experimental | Consecutive patients presenting with suspected acute coronary syndrome for 12 months after the implementation of the sixth generation hs-cTnT assay will be enrolled into the "post-implementation" arm, where care is guided by the sixth-generation assay Receives: Diagnostic Test: sixth-generation high sensitivity cardiac troponin T assay |
What is being measured
The primary outcome is the main question the study is designed to answer.
Length of stay within the Emergency Department
Length of stay within the Emergency Department, defined as the time from arrival until discharge from the Emergency Department or referral for admission to hospital.
Measured: From Emergency Department arrival until Emergency Department discharge or hospital admission, up to 7 days
Secondary outcomes (19)
Length of hospital stay
Total length of hospital stay from presentation until discharge from hospital
Measured: From initial presentation until hospital discharge, up to 1 year
Hospital admission
Admission to hospital during index presentation
Measured: From initial presentation to the Emergency Department up to 7 days
Serial cardiac troponin measurements
Number of serial cardiac troponin measurements during index admission
Measured: From initial presentation until hospital discharge, up to 1 year
Cardiovascular death at 30 days
Cardiovascular death at 30 days following presentation defined according to the Standardized Data Collection for Cardiovascular Trials Initiative: deaths that result from an AMI, sudden cardiac death, death due to heart failure (HF), death due to stroke, death due to CV procedures, death due to CV hemorrhage, and death due to other CV causes (ICD10 codes I00-I99, limited to positions 1 or 2 in the record of death)
Measured: From initial presentation until 30 days after initial presentation
Cardiovascular death at 1 year
Cardiovascular death at 30 days following presentation defined according to the Standardized Data Collection for Cardiovascular Trials Initiative: deaths that result from an AMI, sudden cardiac death, death due to heart failure (HF), death due to stroke, death due to CV procedures, death due to CV hemorrhage, and death due to other CV causes (ICD10 codes I00-I99, limited to positions 1 or 2 in the record of death)
Measured: From initial presentation until 1 year after initial presentation
Myocardial infarction after discharge at 30 days
Myocardial infarction following discharge from hospital at 30 days (a hospital episode recorded in the Scottish Morbidity Record associated with ICD10 codes I21 or I22, limited to position 1 or 2 on the discharge list)
Measured: From initial hospital discharge until 30 days following index presentation
Myocardial infarction after discharge at 1 year
Myocardial infarction following discharge from hospital at 30 days (a hospital episode recorded in the Scottish Morbidity Record associated with ICD10 codes I21 or I22, limited to position 1 or 2 on the discharge list)
Measured: From initial hospital discharge until 1 year following index presentation
Reattendance with suspected myocardial infarction at 30 days
A subsequent attendance to an Emergency Department or Acute Medical Unit during which a clinician responsible for care requests measurement of cardiac troponin for suspected acute coronary syndrome.
Measured: From initial hospital discharge until 30 days following initial presentation.
Reattendance with suspected myocardial infarction at 1 year
A subsequent attendance to an Emergency Department or Acute Medical Unit during which a clinician responsible for care requests measurement of cardiac troponin for suspected acute coronary syndrome.
Measured: From initial hospital discharge until 1 year following initial presentation.
Unscheduled coronary revascularisation at 30 days
Percutaneous coronary intervention or coronary artery bypass graft surgery undertaken on an urgent or emergency basis, excluding revascularisation undertaken during the index admission.
Measured: From initial hospital discharge until 30 days following initial presentation
Unscheduled coronary revascularisation at 1 year
Percutaneous coronary intervention or coronary artery bypass graft surgery undertaken on an urgent or emergency basis, excluding revascularisation undertaken during the index admission.
Measured: From initial hospital discharge until 1 year following initial presentation
Hospitalisation due to heart failure at 30 days
A hospital episode recorded in the Scottish Morbidity Record associated with ICD10 code I25.5 or I50, limited to position 1 or 2 on the discharge list.
Measured: From discharge from the initial hospital attendance until 30 days from initial presentation
Hospitalisation due to heart failure at 1 year
A hospital episode recorded in the Scottish Morbidity Record associated with ICD10 code I25.5 or I50, limited to position 1 or 2 on the discharge list.
Measured: From discharge from the initial hospital attendance until 1 year from initial presentation
Death at 30 days
Death due to any cause
Measured: From initial presentation until 30 days
Death at 1 year
Death due to any cause
Measured: From initial presentation until 1 year
Myocardial injury
Any cardiac troponin measurement above the sex-specific 99th percentile upper reference limit of the relevant assay, during the first 24 hours of the initial presentation to hospital.
Measured: From initial presentation to hospital until 24 hours after presentation.
Index myocardial infarction
Myocardial infarction during the index presentation to hospital (ICD10 codes I21 or I22 associated with the episode in the Scottish Morbidity Record, restricted to position 1 or 2
Measured: From initial presentation until hospital discharge, up to 1 year
Coronary angiography within 30 days
Invasive coronary angiography performed within 30 days of the initial presentation to hospital.
Measured: From initial presentation until 30 days later
Time until initial troponin test
Time from the arrival in the Emergency Department until collection of the first high-sensitivity cardiac troponin test.
Measured: From initial presentation to hospital until 24 hours after presentation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2026
- Study start1 Jun 2026
- Primary completionMay 2028 (estimated)
- Study completionMay 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- More trials run by University of EdinburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- Prospective controlled before-and-after study
- Masking
- None (open label)
- Enrolment
- 19,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Edinburgh
- Sponsor type
- University, hospital or other
- Collaborators
- Roche Diagnostic Ltd.
- Responsible party
- Sponsor
- Investigators
- Andrew R Chapman, MD PhD, Principal investigator, University of Edinburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07636642
- Sponsor's protocol ID
- AC25189
- Acronym
- STEREO-MI
- Status last verified
- Jul 2026
- First submitted
- 22 May 2026
- Last updated
- 7 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The individual data underlying the study can be made available via a Secure Data Environment to approved researchers on application to DataLoch (dataloch@ed.ac.uk)
Publications
Boeddinghaus J, Li Z, Bularga A, Taggart C, Wereski R, Chapman AR, Lee KK, Tuck C, Gunn R, Jenks S, McCance K, Pattenden R, Malo J, Thurston AJF, Tew YY, McDermott M, Gray A, Cruden NLM, Anand A, Kimenai DM, Mills NL; TWITCH-ED Investigators. Clinical Decisions and Outcomes After Switching High-Sensitivity Cardiac Troponin Assays in Suspected ACS: An Interrupted Time-Series Study. JAMA Cardiol. 2026 Feb 1;11(2):186-192. doi: 10.1001/jamacardio.2025.4661.
PubMed 41405901Thurston AJF, Tew YY, Lopez-Ayala P, Koechlin L, O'Brien R, Lynch S, Cooper JG, Fujisawa T, Bima P, McDermott M, Tuck C, Mizerska M, Highton-Williamson E, McCurrach F, Lowry MTH, Doudesis D, Anand A, Lee KK, Ferry AV, Chapman A, Newby DE, Boeddinghaus J, Mueller C, Gray AJ, Mills NL; POC-ET and APACE Investigators. Early Rule Out of Myocardial Infarction With a Novel High-Sensitivity Cardiac Troponin T Assay. JAMA Cardiol. 2026 Jun 1;11(6):583-592. doi: 10.1001/jamacardio.2026.0477.
PubMed 42018311
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sixth Generation High-sensitivity Cardiac Troponin T for the Early Rule Out of Myocardial Infarction: a Controlled Before and After Study
- ClinicalTrials.gov ID
- NCT07636642
- Acronym / sponsor ID
- STEREO-MI / AC25189
- Conditions
- Myocardial Infarction
- Keywords
- cardiac troponin, myocardial infarction, acute coronary syndrome, accelerated decision pathway, Troponin T high sensitivity generation six
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 19,500 participants (estimated)
- Lead sponsor
- University of EdinburghUniversity, hospital or other
- Collaborators
- Roche Diagnostic Ltd.
- Study start
- 1 Jun 2026 (actual)
- Primary completion
- May 2028 (estimated)
- Study completion
- May 2029 (estimated)
- First posted
- 9 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiac troponin is a protein released into the blood when the heart muscle is damaged. Measuring this protein helps doctors diagnose a heart attack (also called a myocardial infarction). Modern blood tests, known as high-sensitivity cardiac troponin assays, can detect very small amounts of this protein.
A new version of this test, called Troponin T high-sensitivity Gen 6, has recently been developed and approved for use. It is designed to be more accurate and reliable, detecting smaller changes in troponin levels and being less affected by technical interference. The investigators believe this improved test will allow doctors to diagnose heart attacks more quickly and decide sooner who needs to stay in hospital and who can safely go home. This could help reduce overcrowding in Accident and Emergency (A\&E) departments, a major challenge for the NHS.
This study will examine whether switching to this new test across a health board shortens the time patients with suspected heart attacks spend in the Emergency Department. The investigators will use information from the DataLoch Heart Disease Registry, which automatically collects anonymised hospital data for patients attending with possible heart attacks. The investigators will compare data from one year before and one year after implementation to see whether average length of stay changes and to confirm that patient safety remains high. This investigators will also measure both the current and new versions of the troponin test in surplus blood samples collected during two six-month periods-one before and one after the new test is introduced. This will allows the investigators to directly compare the two tests reliably.
Patients will not need to do anything extra to take part - the study uses information and samples already collected as part of their usual care.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Prospective controlled before-and-after study
| Arm | Type | Receives |
|---|---|---|
| Pre-implementation | Active comparator | Diagnostic Test: fifth-generation high sensitivity cardiac troponin T assayConsecutive patients presenting with suspected acute coronary syndrome for 12 months prior to the implementation of the sixth generation hs-cTnT assay will be enrolled into the "pre-implementation" arm, where care is guided by the current, fifth-generation assay |
| Post-implementation | Experimental | Diagnostic Test: sixth-generation high sensitivity cardiac troponin T assayConsecutive patients presenting with suspected acute coronary syndrome for 12 months after the implementation of the sixth generation hs-cTnT assay will be enrolled into the "post-implementation" arm, where care is guided by the sixth-generation assay |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age 18 years and over.
- Attending clinician suspects acute coronary syndrome.
- At least one measurement of cardiac troponin using the Gen 5 or Gen 6 hs-cTnT assay.
Key exclusion criteria (3 listed)
- Insufficient clinical information to perform record linkage.
- Not resident in Scotland.
- Previous enrolment in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sixth-generation high sensitivity cardiac troponin T assayAlso: Troponin T high sensitivity generation six, TnT hs Gen 6Elecsys Troponin T hs Gen 6 is an immunoassay for the in vitro quantitative determination of cardiac troponin T in human serum and plasma, that can be used as an aid in the differential diagnosis of acute coronary syndrome to identify necrosis, e.g. acute myocardial infarction (AMI). In contrast to the previous generation of the assay (Elecsys Troponin T hs), the Gen 6 assay has been standardised against recombinant human cardiac troponin T, and has been demonstrated to have greater analytical precision and resistance to interference. | Diagnostic test | Post-implementation |
| fifth-generation high sensitivity cardiac troponin T assayAlso: Troponin T gen 5Elecsys Troponin T Gen 5 is an immunoassay for the in vitro quantitative determination of cardiac troponin T in human serum and plasma, that can be used as an aid in the differential diagnosis of acute coronary syndrome to identify necrosis, e.g. acute myocardial infarction (AMI). It is the most widely used high-sensitivity troponin assay globally. | Diagnostic test | Pre-implementation |
Primary outcome
Length of stay within the Emergency Department
Time frame: From Emergency Department arrival until Emergency Department discharge or hospital admission, up to 7 days
Length of stay within the Emergency Department, defined as the time from arrival until discharge from the Emergency Department or referral for admission to hospital.
19 secondary outcomes
Length of hospital stay
Time frame: From initial presentation until hospital discharge, up to 1 year
Hospital admission
Time frame: From initial presentation to the Emergency Department up to 7 days
Serial cardiac troponin measurements
Time frame: From initial presentation until hospital discharge, up to 1 year
Cardiovascular death at 30 days
Time frame: From initial presentation until 30 days after initial presentation
Cardiovascular death at 1 year
Time frame: From initial presentation until 1 year after initial presentation
Myocardial infarction after discharge at 30 days
Time frame: From initial hospital discharge until 30 days following index presentation
Myocardial infarction after discharge at 1 year
Time frame: From initial hospital discharge until 1 year following index presentation
Reattendance with suspected myocardial infarction at 30 days
Time frame: From initial hospital discharge until 30 days following initial presentation.
Reattendance with suspected myocardial infarction at 1 year
Time frame: From initial hospital discharge until 1 year following initial presentation.
Unscheduled coronary revascularisation at 30 days
Time frame: From initial hospital discharge until 30 days following initial presentation
Unscheduled coronary revascularisation at 1 year
Time frame: From initial hospital discharge until 1 year following initial presentation
Hospitalisation due to heart failure at 30 days
Time frame: From discharge from the initial hospital attendance until 30 days from initial presentation
Hospitalisation due to heart failure at 1 year
Time frame: From discharge from the initial hospital attendance until 1 year from initial presentation
Death at 30 days
Time frame: From initial presentation until 30 days
Death at 1 year
Time frame: From initial presentation until 1 year
Myocardial injury
Time frame: From initial presentation to hospital until 24 hours after presentation.
Index myocardial infarction
Time frame: From initial presentation until hospital discharge, up to 1 year
Coronary angiography within 30 days
Time frame: From initial presentation until 30 days later
Time until initial troponin test
Time frame: From initial presentation to hospital until 24 hours after presentation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
- Background: PubMed 41405901Boeddinghaus J, Li Z, Bularga A, Taggart C, Wereski R, Chapman AR, Lee KK, Tuck C, Gunn R, Jenks S, McCance K, Pattenden R, Malo J, Thurston AJF, Tew YY, McDermott M, Gray A, Cruden NLM, Anand A, Kimenai DM, Mills NL; TWITCH-ED Investigators. Clinical Decisions and Outcomes After Switching High-Sensitivity Cardiac Troponin Assays in Suspected ACS: An Interrupted Time-Series Study. JAMA Cardiol. 2026 Feb 1;11(2):186-192. doi: 10.1001/jamacardio.2025.4661.
- Background: PubMed 42018311Thurston AJF, Tew YY, Lopez-Ayala P, Koechlin L, O'Brien R, Lynch S, Cooper JG, Fujisawa T, Bima P, McDermott M, Tuck C, Mizerska M, Highton-Williamson E, McCurrach F, Lowry MTH, Doudesis D, Anand A, Lee KK, Ferry AV, Chapman A, Newby DE, Boeddinghaus J, Mueller C, Gray AJ, Mills NL; POC-ET and APACE Investigators. Early Rule Out of Myocardial Infarction With a Novel High-Sensitivity Cardiac Troponin T Assay. JAMA Cardiol. 2026 Jun 1;11(6):583-592. doi: 10.1001/jamacardio.2026.0477.
- Individual participant dataSharing planned: Yes. The individual data underlying the study can be made available via a Secure Data Environment to approved researchers on application to DataLoch (dataloch@ed.ac.uk)
Related trials for Myocardial Infarction
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Enrolling by invitation
The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
Coronary Atherosclerosis and Other Heart Disease, Cardiovascular Diseases
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Andrew R Chapman, MD PhD principal investigator
University of Edinburgh
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing sixth-generation high sensitivity cardiac troponin T assay and fifth-generation high sensitivity cardiac troponin T assay in people with Myocardial Infarction, run by University of Edinburgh at 3 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andrew R Chapman, MD PhD (+44131 242 6200, a.r.chapman@ed.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Length of stay within the Emergency Department (time frame: From Emergency Department arrival until Emergency Department discharge or hospital admission, up to 7 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07636642, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.